Mandate

Vinge advises Altor, the founders and the other sellers in connection with the divestment of a majority share in Eleda to Bain Capital

Vinge advises Altor Funds (“Altor”), the founders and the other sellers in connection with Bain Capital Private Equity (“Bain Capital”), a leading global private investment firm, acquiring a controlling stake in Eleda from Altor, which will reinvest a minority share. Eleda’s founders, Johan Halvardsson and Peter Condrup, and senior executives in Eleda will also reinvest a substantial share. Through the transaction, Altor, Eleda and Bain Capital establish a partnership for future expansion.

Headquartered in Stockholm and with approximately 3,000 employees, Eleda is a leading Nordic infrastructure development and services provider. The company is the market leader within several segments, many addressing the need of the green transition, including water and sewerage, power distribution, district heating, roads, data centres, railways, and electric vehicle charging stations. Eleda’s decentralised operating model allows its group companies to deliver the highest quality to their customers with the optimal mix of local presence and the resources of a larger organization.

The transaction is subject to regulatory approvals.

Vinge’s team consisted mainly of Christina Kokko, Johanna Wiberg, Carl Fredrik Wachtmeister, Ellen Flygt, Philip Moré, Jonatan Stentorp, Jonas Johansson, Nina Gransäter and Johan Gavelin (M&A), Louise Brorsson Salomon and Jolinn Uhlin (Banking and Finance), Martin Johansson and Hedvig Josefson (EU Regulatory), Emy Rydén, Emelie Schoning, Gabriella Balbo, Emma Emsjö, Christoffer Widström and Fanny Askelöf (Transaction Support Coordinators).

Read the client’s press release           

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026